Predictive and prognostic value of ZEB1 protein expression in breast cancer patients with neoadjuvant chemotherapy

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

(2018) Sibylle Loibl et al.   LANCET ONCOLOGY

ZEB1 confers chemotherapeutic resistance to breast cancer by activating ATM

(2018) Xiang Zhang et al.   Cell Death & Disease

A stemness-related ZEB1–MSRB3 axis governs cellular pliancy and breast cancer genome stability

(2017) Anne-Pierre Morel et al.   NATURE MEDICINE

Clinicopathological significance of ZEB-1 and E-cadherin proteins in patients with oral cavity squamous cell carcinoma

(2017) Xiaofeng Yao et al.   OncoTargets and Therapy

Phosphorylation Regulates Functions of ZEB1 Transcription Factor

(2016) M. Candelaria Llorens et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Pathological Complete Response in Neoadjuvant Treatment of Breast Cancer

(2015) Patricia Cortazar et al.   ANNALS OF SURGICAL ONCOLOGY

Expression of epithelial-mesenchymal transition–related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome

(2015) Min Hye Jang et al.   HUMAN PATHOLOGY

Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer

(2015) Silvia Prislei et al.   Oncotarget

ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism

(2014) Yanan Yang et al.   JOURNAL OF CLINICAL INVESTIGATION

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1

(2014) Peijing Zhang et al.   NATURE CELL BIOLOGY

ASPP2 controls epithelial plasticity and inhibits metastasis through β-catenin-dependent regulation of ZEB1

(2014) Yihua Wang et al.   NATURE CELL BIOLOGY

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC)

(2013) Motoyuki Hashiguchi et al.   BMC CANCER

CUL4A Induces Epithelial–Mesenchymal Transition and Promotes Cancer Metastasis by Regulating ZEB1 Expression

(2013) Yunshan Wang et al.   CANCER RESEARCH

The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance

(2013) Florian A. Siebzehnrubl et al.   EMBO Molecular Medicine

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

(2012) José Baselga et al.   LANCET

Repression of E-cadherin by SNAIL, ZEB1, and TWIST in invasive ductal carcinomas of the breast: a cooperative effort?☆

(2010) Núria Montserrat et al.   HUMAN PATHOLOGY

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

(2009) Balazs Györffy et al.   BREAST CANCER RESEARCH AND TREATMENT

Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer

(2009) T. Arumugam et al.   CANCER RESEARCH

The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1

(2008) Philip A. Gregory et al.   NATURE CELL BIOLOGY